Z Gastroenterol 2025; 63(05): e322
DOI: 10.1055/s-0045-1809204
Abstracts
2. Gastroenterologie

Treatment patterns of eosinophilic esophagitis in the biologic era – an Austrian real-world analysis

Authors

  • J Pokryszka

    1   Medizinische Unversität Wien, Gastroenterologie und Hepatologie, Wien, Austria

  • M Weitersberger

    2   Ordensklinikum Linz Barmherzige Schwester, Gastroenterologie und Hepatologi, Linz, Austria

  • P Dinkhauser

    3   Klinikum Wels-Grieskirchen, Gastroenterologie und Hepaologie, Wels-Grieskirchen, Austria

  • K Steidl

    4   Barmherzige Brüder St. Veit, Gastroenterologie und Hepatologie, St. Veit an der Glan, Austria

  • T Horvatits

    5   Gastromedics, Gastroenterologie, Eisenstadt, Austria

  • M Häfner

    6   Klinikum Barmherzige Schwestern Wien, Innere Medizin 2, Wien, Austria

  • L Kazemi-Shirazi

    1   Medizinische Unversität Wien, Gastroenterologie und Hepatologie, Wien, Austria

  • G Novacek

    1   Medizinische Unversität Wien, Gastroenterologie und Hepatologie, Wien, Austria

  • M Trauner

    1   Medizinische Unversität Wien, Gastroenterologie und Hepatologie, Wien, Austria

  • W Sieghart

    7   Imed 19, Gastroenterologie, Wien, Austria

  • H Schlager

    8   Medizinische Unversität Graz, Gastroenterologie und Hepatologie, Wien, Austria

  • P Schreiner

    1   Medizinische Unversität Wien, Gastroenterologie und Hepatologie, Wien, Austria
Further Information
Also available at
 

Introduction Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease requiring a long-term maintenance treatment. The data of therapy patterns and treatment durability in patients with eosinophilic esophagitis in the biologic era are scarce in a real-world setting

Material and Methods Data on patients’ demographics, concomitant atopic diseases and different treatments were collected retrospectively at seven Austrian centers. The eligible subjects had to start their first therapy between January 2014 and February 2025. The reasons for change of therapy and the last endoscopy were recorded.

Results In total, 336 patients (30.1% female) were analyzed of whom 34.5% of them remained on the 1st line treatment. In a mean time of 7.6 months a 2nd line treatment was started in 65.5%, but only a minority (41%) remained on this therapy. The most common 1st line treatment was swallowed topical corticosteroids (STCs) (54.2%) followed by proton pump inhibitors (22.3%) and food elimination diet (20/336, 6.0%). In contrast to only a minority who stayed on PPI therapy after starting it (21.3%), the majority of patients had ongoing STC treatment (51%) or therapy was stopped due to clinical and histological remission (27%). Forty (11.9%) patients received a treatment with dupilumab of whom 7.5% as first line treatment (because of multiple type 2 inflammatory diseases) and the majority as second line treatment (57.5%). The reason for dupilumab was mostly due to non-response to STC (55%) followed by side effects (35%). 95% (38/40) of them remained on dupilumab until the last follow-up.

Conclusion Although most patients receive STC at the beginning, the majority need multiple treatment lines. Dupilumab is used in a tenth of patients due to refractoriness, side-effects or treatment of other type 2 inflammatory diseases.



Publication History

Article published online:
13 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany